FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379334544> ?p ?o ?g. }

• W4379334544 endingPage "e19540" @default.
• W4379334544 startingPage "e19540" @default.
• W4379334544 abstract "e19540 Background: Brexucabtagene autoleucel (brexu-cel) is approved for relapsed/refractory mantle cell lymphoma (MCL). Cyclophosphamide/fludarabine for lymphodepletion (LD) is standard LD prior to brexu-cel. Due to a recent fludarabine shortage as well as institutional practice, we have utilized alternatives to fludarabine-based LD prior to brexu-cel, predominantly bendamustine. Bendamustine is an attractive option because it is included in the label for another anti-CD19 CAR T cell product. We report our institutional experience with bendamustine LD followed by brexu-cel. Methods: We retrospectively examined our institutional records for all patients with MCL who were treated with bendamustine LD followed by brexu-cel from 2020-2022. Progression-free survival (PFS) was analyzed with Kapalan-Meier survival analysis. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded per ASTCT criteria. Results: 16 patients received bendamustine followed by brexu-cel. Median age was 65 years (range: 54-76). Median number of prior therapies was 3 (range: 3-8). All patients (100%) had received a BTK inhibitor prior to brexu-cel. 14/16 (88%) received bridging therapy. 14/16 (88%) patients had CRS; 11/14 (79%) had grade 1-2 CRS and 3 (21%) had grade 3 or greater CRS. 5 (31%) patients had ICANS; 2 (40%) had grade 1-2 ICANS, and 3 (60%) had grade 3 or greater ICANS. 10 (63%) patients received tocilizumab, 8 (50%) received dexamethasone, and 3 (19%) received anakinra for management of CRS and/or ICANS. Best objective response rate (ORR) was 81% with 11 (69%) patients achieving CR. Median follow-up was 13.4 months. Estimated 6-month progression-free survival was 86% (95%CI: 54-96%) and 12-month progression-free survival was 63% (95%CI: 32-82). Conclusions: Bendamustine LD prior to brexu-cel for MCL is feasible, and, although these numbers are small, appears to have comparable outcomes to that reported in real world brexu-cel data (best ORR 90% with 82% CR rate, 6 month PFS estimate 69%, 12 month PFS estimate 59%; Y Wang et al. J Clin Oncol 2023) and ZUMA-2 outcomes (93% ORR with 67% CR rate, 12 month PFS estimate 61%; M Wang et al. NEJM 2020)." @default.
• W4379334544 created "2023-06-05" @default.
• W4379334544 creator A5005058090 @default.
• W4379334544 creator A5015896987 @default.
• W4379334544 creator A5019666650 @default.
• W4379334544 creator A5038647887 @default.
• W4379334544 creator A5039776999 @default.
• W4379334544 creator A5042844727 @default.
• W4379334544 creator A5069919728 @default.
• W4379334544 creator A5080630441 @default.
• W4379334544 creator A5088286702 @default.
• W4379334544 date "2023-06-01" @default.
• W4379334544 modified "2023-09-30" @default.
• W4379334544 title "Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma." @default.
• W4379334544 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e19540" @default.
• W4379334544 hasPublicationYear "2023" @default.
• W4379334544 type Work @default.
• W4379334544 citedByCount "0" @default.
• W4379334544 crossrefType "journal-article" @default.
• W4379334544 hasAuthorship W4379334544A5005058090 @default.
• W4379334544 hasAuthorship W4379334544A5015896987 @default.
• W4379334544 hasAuthorship W4379334544A5019666650 @default.
• W4379334544 hasAuthorship W4379334544A5038647887 @default.
• W4379334544 hasAuthorship W4379334544A5039776999 @default.
• W4379334544 hasAuthorship W4379334544A5042844727 @default.
• W4379334544 hasAuthorship W4379334544A5069919728 @default.
• W4379334544 hasAuthorship W4379334544A5080630441 @default.
• W4379334544 hasAuthorship W4379334544A5088286702 @default.
• W4379334544 hasConcept C126322002 @default.
• W4379334544 hasConcept C141071460 @default.
• W4379334544 hasConcept C143998085 @default.
• W4379334544 hasConcept C2776694085 @default.
• W4379334544 hasConcept C2776755627 @default.
• W4379334544 hasConcept C2777525834 @default.
• W4379334544 hasConcept C2779263901 @default.
• W4379334544 hasConcept C2779338263 @default.
• W4379334544 hasConcept C2780653079 @default.
• W4379334544 hasConcept C2781442060 @default.
• W4379334544 hasConcept C71924100 @default.
• W4379334544 hasConceptScore W4379334544C126322002 @default.
• W4379334544 hasConceptScore W4379334544C141071460 @default.
• W4379334544 hasConceptScore W4379334544C143998085 @default.
• W4379334544 hasConceptScore W4379334544C2776694085 @default.
• W4379334544 hasConceptScore W4379334544C2776755627 @default.
• W4379334544 hasConceptScore W4379334544C2777525834 @default.
• W4379334544 hasConceptScore W4379334544C2779263901 @default.
• W4379334544 hasConceptScore W4379334544C2779338263 @default.
• W4379334544 hasConceptScore W4379334544C2780653079 @default.
• W4379334544 hasConceptScore W4379334544C2781442060 @default.
• W4379334544 hasConceptScore W4379334544C71924100 @default.
• W4379334544 hasIssue "16_suppl" @default.
• W4379334544 hasLocation W43793345441 @default.
• W4379334544 hasOpenAccess W4379334544 @default.
• W4379334544 hasPrimaryLocation W43793345441 @default.
• W4379334544 hasRelatedWork W1867956999 @default.
• W4379334544 hasRelatedWork W2014285677 @default.
• W4379334544 hasRelatedWork W2079542323 @default.
• W4379334544 hasRelatedWork W2103857518 @default.
• W4379334544 hasRelatedWork W2193278586 @default.
• W4379334544 hasRelatedWork W2320013149 @default.
• W4379334544 hasRelatedWork W2524396226 @default.
• W4379334544 hasRelatedWork W2900648479 @default.
• W4379334544 hasRelatedWork W4233157026 @default.
• W4379334544 hasRelatedWork W4308653587 @default.
• W4379334544 hasVolume "41" @default.
• W4379334544 isParatext "false" @default.
• W4379334544 isRetracted "false" @default.
• W4379334544 workType "article" @default.